Myomo to Report Third Quarter Financial Results on November 7, 2023

Rhea-AI Summary

Myomo, a wearable medical robotics company, will report financial results for Q3 and 9M 2023 on November 7, 2023. The company will host a conference call with prepared remarks by the CEO and CFO. Participants can pre-register for the call and access it through a webcast or dial-in. A replay will be available.

BOSTON--(BUSINESS WIRE)-- Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the three and nine months ended September 30, 2023 on November 7, 2023.

The Company will host a conference call the same day, Tuesday November 7, 2023 at 4:30 p.m. ET with prepared remarks by Paul R. Gudonis, chairman and chief executive officer, and David Henry, chief financial officer.

Participants are encouraged to pre-register for the conference call using this link. Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start time. Those without internet access or unable to pre-register may dial in by calling, 1-844-707-6932 (U.S.) or 1-412-317-9250 (International). A webcast of the call may also be accessed at Myomo’s Investor Relations page at http://ir.myomo.com/.

A replay of the webcast will be available beginning approximately one hour after the completion of the live conference call at http://ir.myomo.com/. A dial-in replay of the call will be available until November 21, 2023; please dial 1-877-344-7529 (U.S. toll free), 855-669-9658 (Canada toll free) or 1-412-317-0088 (International toll) and provide the access code 5227358.

About Myomo, Inc.

Myomo, Inc. is a wearable medical robotics company that offers improved arm and hand function for those suffering from neurological disorders and upper limb paralysis. Myomo develops and markets the MyoPro product line. MyoPro is a powered upper limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury, ALS or other neuromuscular disease or injury. It is currently the only marketed device that, sensing a patient’s own EMG signals through non-invasive sensors on the arm, can restore an individual’s ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. Many are able to return to work, live independently and reduce their cost of care. Myomo is headquartered in Boston, Massachusetts, with sales and clinical professionals across the U.S and representatives internationally. For more information, please visit www.myomo.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231031114683/en/

For Myomo:

ir@myomo.com

Investor Relations:

Kim Sutton Golodetz

LHA Investor Relations

212-838-3777

kgolodetz@lhai.com

Source: Myomo, Inc.

FAQ

When will Myomo report its financial results for Q3 and 9M 2023?

Myomo will report its financial results for Q3 and 9M 2023 on November 7, 2023.

Who will be giving prepared remarks during the conference call?

Paul R. Gudonis, chairman and chief executive officer, and David Henry, chief financial officer, will be giving prepared remarks during the conference call.

How can participants pre-register for the conference call?

Participants can pre-register for the conference call by using the provided link.

How can participants access the conference call?

Participants can access the conference call through a webcast or by dialing in.

Will there be a replay of the conference call available?

Yes, a replay of the conference call will be available through a webcast and dial-in.